Brief: Aurobindo Pharma Unit Receives EIR From US FDA; Inspection Closed
20/03/2026 04:29
March 20 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: AUROBINDO PHARMA - US FDA INSPECTS UNIT-V API FACILITY OF APITORIA PHARMA, AUROBINDO SUBSIDIARY AUROBINDO PHARMA - UNIT-V RECEIVES EIR CLASSIFYING FACILITY AS VAI; INSPECTION CLOSED Source text: ID:nBSE9t0t0d Further company coverage: ARBN.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11